A number of other research firms also recently commented on NVS. BMO Capital Markets increased their target price on shares of Novartis from $118.00 to $120.00 and gave the company a "market perform" rating in a research report on Wednesday, October 30th. Erste Group Bank reiterated a "hold" rating on shares of Novartis in a research report on Tuesday, November 19th. HSBC downgraded Novartis from a "hold" rating to a "reduce" rating in a report on Wednesday, December 4th. Finally, Deutsche Bank Aktiengesellschaft raised Novartis from a "hold" rating to a "buy" rating in a research report on Tuesday. Two investment analysts have rated the stock with a sell rating, five have assigned a hold rating, one has issued a buy rating and one has assigned a strong buy rating to the company. According to data from MarketBeat.com, Novartis presently has a consensus rating of "Hold" and an average price target of $123.38.
Check Out Our Latest Research Report on NVS
Shares of NYSE NVS opened at $106.17 on Friday. The business has a 50-day moving average of $100.32 and a two-hundred day moving average of $108.41. The company has a market capitalization of $217.00 billion, a price-to-earnings ratio of 18.06, a price-to-earnings-growth ratio of 1.51 and a beta of 0.58. Novartis has a 1 year low of $92.35 and a 1 year high of $120.92. The company has a debt-to-equity ratio of 0.55, a current ratio of 1.11 and a quick ratio of 0.90.
Novartis (NYSE:NVS - Get Free Report) last posted its earnings results on Friday, January 31st. The company reported $1.98 earnings per share for the quarter, topping the consensus estimate of $1.80 by $0.18. Novartis had a return on equity of 37.79% and a net margin of 23.56%. On average, analysts forecast that Novartis will post 8.34 earnings per share for the current fiscal year.
Institutional investors have recently added to or reduced their stakes in the stock. Centaurus Financial Inc. increased its holdings in shares of Novartis by 1.7% in the third quarter. Centaurus Financial Inc. now owns 5,728 shares of the company's stock valued at $659,000 after purchasing an additional 98 shares during the period. FLC Capital Advisors grew its position in Novartis by 4.4% in the 3rd quarter. FLC Capital Advisors now owns 2,366 shares of the company's stock valued at $272,000 after buying an additional 100 shares during the last quarter. Clear Harbor Asset Management LLC increased its stake in Novartis by 2.3% in the 3rd quarter. Clear Harbor Asset Management LLC now owns 4,423 shares of the company's stock valued at $509,000 after buying an additional 100 shares during the period. Allen Wealth Management LLC raised its position in Novartis by 1.8% during the 3rd quarter. Allen Wealth Management LLC now owns 5,788 shares of the company's stock worth $666,000 after buying an additional 100 shares during the last quarter. Finally, WealthPlan Investment Management LLC lifted its stake in shares of Novartis by 1.1% in the 3rd quarter. WealthPlan Investment Management LLC now owns 9,494 shares of the company's stock worth $1,092,000 after acquiring an additional 100 shares during the period. Institutional investors and hedge funds own 13.12% of the company's stock.
Novartis AG engages in the research, development, manufacture, and marketing of healthcare products in Switzerland and internationally. The company offers prescription medicines for patients and physicians. It focuses on therapeutic areas, such as cardiovascular, renal and metabolic, immunology, neuroscience, and oncology, as well as ophthalmology and hematology.
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to [email protected].
Before you make your next trade, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis.
Our team has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and none of the big name stocks were on the list.
They believe these five stocks are the five best companies for investors to buy now...
See The Five Stocks Here
Before you consider Novartis, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Novartis wasn't on the list.
While Novartis currently has a "Reduce" rating among analysts, top-rated analysts believe these five stocks are better buys.